홈
마켓
차트 & 아이디어
Algo
뉴스
스토어
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
히트맵
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
P
PRN
Invesco Dorsey Wright Industrials Momentum ETF
245.7
8
USD
-0.86%
부문:
금융
베이스:
USD
수익 통화:
USD
일일 변동 비율
년간 변동
일일 변동
-0.86%
월간 변동
+9.00%
6달 변화
+45.15%
년간 변동율
+65.72%
이전 종가
247.9
1
Open
243.5
0
저가
243.5
0
High
245.7
8
양
42
마켓
US ETFs
PRN
전체 차트 열기
Full chart
개요
모든 보유 자산
히트맵
주요 보유 종목
Market Value
Shares
Weight %
Invesco Private Prime Fund
28.59 M
28.59 M
8.73%
FIX
Comfort Systems USA, Inc.
19.84 M
17.37 K
6.05%
PWR
Quanta Services, Inc.
16.52 M
34.81 K
5.04%
PL
Planet Labs PBC
16.26 M
651.02 K
4.96%
HWM
Howmet Aerospace Inc.
15.93 M
76.54 K
4.86%
CMI
Cummins Inc.
12.01 M
20.75 K
3.67%
JBL
Jabil Inc.
11.80 M
49.74 K
3.60%
Invesco Private Government Fund
11.00 M
11.00 M
3.36%
CAT
Caterpillar Inc.
10.17 M
15.46 K
3.10%
GE
General Electric Co.
9.96 M
32.45 K
3.04%
CW
Curtiss-Wright Corp.
9.66 M
14.70 K
2.95%
DY
Dycom Industries, Inc.
9.34 M
25.63 K
2.85%
TPC
Tutor Perini Corp.
8.78 M
111.34 K
2.68%
MTZ
MasTec, Inc.
8.60 M
35.76 K
2.62%
PH
Parker-Hannifin Corp.
8.37 M
8 943.00
2.55%
RUN
Sunrun Inc.
7.95 M
418.35 K
2.43%
TEL
TE Connectivity PLC
7.91 M
35.51 K
2.41%
VSEC
VSE Corp.
7.66 M
35.05 K
2.34%
HEI
HEICO Corp.
7.55 M
22.83 K
2.31%
MLI
Mueller Industries, Inc.
7.39 M
54.27 K
2.25%
1
2
3
뉴스
First Quarter Earnings: Sharpening Sector Divergence
Empire State Manufacturing Survey: Highest Level In Four Years
Industrials Momentum ETF (PRN) Touches a New 52-Week High
Iran Conflict And Energy Markets: The Initial Response From Active Managers
Australia stocks lower at close of trade; S&P/ASX 200 down 0.57%
Should You Invest in the Invesco Dorsey Wright Industrials Momentum ETF (PRN)?
Global PMI: Tracking The Sectors Hit Hardest By The Middle East War
Concerns Shift From Obsolescence To Oil
Q4 2025 Earnings: AI Disruption Vs. Traditional Fundamentals
PRN: Elevated Valuations Challenge Future Returns (NASDAQ:PRN)
프로파운드 메디컬, Raymond James 투자의견 재확인
Profound Medical stock rating reiterated by Raymond James on trial data